EA201690215A1 - Соединение и способы для лечения синдрома удлиненного интервала qt - Google Patents

Соединение и способы для лечения синдрома удлиненного интервала qt

Info

Publication number
EA201690215A1
EA201690215A1 EA201690215A EA201690215A EA201690215A1 EA 201690215 A1 EA201690215 A1 EA 201690215A1 EA 201690215 A EA201690215 A EA 201690215A EA 201690215 A EA201690215 A EA 201690215A EA 201690215 A1 EA201690215 A1 EA 201690215A1
Authority
EA
Eurasian Patent Office
Prior art keywords
syndrome
treating
interval
methods
long
Prior art date
Application number
EA201690215A
Other languages
English (en)
Inventor
Луиз Белардинелли
Сридхаран Раджамани
Деван Зенг
Original Assignee
Джилид Сайэнс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джилид Сайэнс, Инк. filed Critical Джилид Сайэнс, Инк.
Publication of EA201690215A1 publication Critical patent/EA201690215A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Предложен способ лечения синдрома удлиненного интервала QT путем введения эффективного количества активного и селективного блокатора ионных каналов, формирующих поздний натриевый ток.
EA201690215A 2013-08-01 2014-07-31 Соединение и способы для лечения синдрома удлиненного интервала qt EA201690215A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361861344P 2013-08-01 2013-08-01
US201361900235P 2013-11-05 2013-11-05
PCT/US2014/049155 WO2015017661A1 (en) 2013-08-01 2014-07-31 Compound and methods for treating long qt syndrome

Publications (1)

Publication Number Publication Date
EA201690215A1 true EA201690215A1 (ru) 2016-07-29

Family

ID=51352867

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690215A EA201690215A1 (ru) 2013-08-01 2014-07-31 Соединение и способы для лечения синдрома удлиненного интервала qt

Country Status (12)

Country Link
US (1) US9126989B2 (ru)
EP (1) EP3027190A1 (ru)
JP (1) JP2016525580A (ru)
KR (1) KR20160035061A (ru)
CN (1) CN105611931A (ru)
AU (1) AU2014296145A1 (ru)
CA (1) CA2919757A1 (ru)
EA (1) EA201690215A1 (ru)
HK (1) HK1219893A1 (ru)
MX (1) MX2016001302A (ru)
SG (1) SG11201600119PA (ru)
WO (1) WO2015017661A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
US10575744B2 (en) 2017-02-24 2020-03-03 Medtronic Cryocath Lp Pericardial balloon mapping

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
TWI478908B (zh) * 2011-07-01 2015-04-01 Gilead Sciences Inc 作為離子通道調節劑之稠合雜環化合物
CA2862670A1 (en) * 2012-01-27 2013-08-01 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers

Also Published As

Publication number Publication date
WO2015017661A1 (en) 2015-02-05
AU2014296145A1 (en) 2016-01-28
JP2016525580A (ja) 2016-08-25
KR20160035061A (ko) 2016-03-30
HK1219893A1 (zh) 2017-04-21
US20150038489A1 (en) 2015-02-05
CA2919757A1 (en) 2015-02-05
MX2016001302A (es) 2016-04-07
CN105611931A (zh) 2016-05-25
EP3027190A1 (en) 2016-06-08
SG11201600119PA (en) 2016-02-26
US9126989B2 (en) 2015-09-08

Similar Documents

Publication Publication Date Title
EA201792613A1 (ru) Модуляторы cot и способы их применения
EA201890411A1 (ru) Терапевтически активные соединения и способы их применения
CR20150225A (es) Piridinonas anti-fibroticas
EP3085439A4 (en) Polyacrylic acid (salt) water absorbent, and method for producing same
MX370818B (es) Anticuerpos anti-b7-h1 para tratar tumores.
PH12015502075B1 (en) Treatment of cataplexy
EA201591615A1 (ru) Замещенные ксантины и способы их применения
EA201690582A1 (ru) Модуляторы фактора в комплемента
PL3069375T3 (pl) Koncentryczne źródło jonów, jonowód i sposób stosowania w jonizacji powierzchniowej APCI
BR112015020159A2 (pt) cartucho, método de fabricação de pelo menos parte do envelope de um cartucho, máquina de preparação de bebidas e sistema de preparação de bebidas
CL2017002238A1 (es) Método de tratamiento con tradipitant
EA202091397A1 (ru) Бензохинолоновые ингибиторы vmat2
IL246202A0 (en) Methods for t-cell epitope sorting, preparation of t-cell preparations and treatment of diseases
MX366765B (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerósis múltiple.
MX2015011386A (es) Metodo para tratar cancer pancreatico.
EA201591709A1 (ru) 5-бром-индирубины
EA201690075A1 (ru) Способ лечения внутриклеточной инфекции
CL2016001488A1 (es) Quinazolin-thf-aminas como inhibidores de pde1
TR201819042T4 (tr) Fibrozis ve kanserlerin tedavisine yönelik yöntemler.
TR201900665T4 (tr) Diyabetik nefropatinin tedavi yöntemi.
EA201690446A1 (ru) Лечение множественной миеломы
EA201690215A1 (ru) Соединение и способы для лечения синдрома удлиненного интервала qt
CL2017002759A1 (es) Método para crear un compuesto a base de mercurio, compuesto a base de mercurio, métodos de uso del compuesto a base de mercurio y usos del compuesto a base de mercurio
EA201690445A1 (ru) Лечение рака
MX2016003248A (es) Metodos de uso de anticuerpos anti-lgr5.